• DSM-Firmenich posted H1 2026 like-for-like sales growth of 5% on sales of €4.66 billion; Q2 sales rose 6% LFL to €2.39 billion.
• H1 adjusted EBITDA rose 7% LFL to €900 million, while the adjusted EBITDA margin slipped 0.2 percentage points to 19.3%.
• Q2 adjusted EBITDA climbed 10% LFL to €466 million; the adjusted EBITDA margin held at 19.5% despite a 70-bps FX headwind.
• Core adjusted EPS increased 14% versus H1 2025 to €1.84; adjusted gross operating free cash flow improved to €320 million from €79 million.
• Outlook unchanged for 2026: 2%-4% organic sales growth, about 20% adjusted EBITDA margin, 11%-12% cash conversion; €500 million buyback progressing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DSM-Firmenich AG published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.